CHICAGO: With biotech stocks in the dumps, investors have been hoping for deals to revive the sector, but lately, merger-and-acquisition( MA) activity has been anaemic. Finally on Tuesday, Pfizer announced it will buy Biohaven Pharmaceutical Holding Company Ltd, a nine-year-old company that makes treatments for migraines, for US$ 11. 6bil( RM51bil). The deal, which gives Pfizer an oral drug already on the market and a nasal spray for migraines that is nearing commercialisation, puts some of its
综合
星报-商业
2022-05-12 00:00:00.0